Sanofi s.a. SNY.US Overview Analysis
)SNY AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock holds a moderate value rating. If you have positions, consider retaining; for new ones, wait for a value score above 4.
SNY Current Performance
-4.28%
Sanofi s.a.
0.38%
Avg of Sector
-0.07%
S&P500
Top 10 High Relevance to SNY
- NVS Novartis agValue 4Trend 2Swing Trading 5Whale Interest 2Dividend 5See more
SNY Profile
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi's Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company's products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.